Öz
Aims: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have gained significant attention in cardiovascular science due to their cardioprotective and Reno protective effects beyond glucose control. Over the past decade, research in this field has expanded rapidly. This study aims to conduct a bibliometric analysis of global research trends on SGLT2 inhibitors in cardiovascular diseases from 2014 to 2024, evaluating publication output, citation impact, influential contributors, keyword trends, and international collaboration networks.
Methods: A bibliometric analysis was performed using the Web of Science (WoS) Core Collection database, focusing on articles published between January 1, 2014, and December 31, 2024, within the “cardiac cardiovascular system” category. VOSviewer software was utilized to visualize author collaborations, institutional affiliations, keyword co-occurrence, and citation distributions.
Results: A total of 1,271 articles were analyzed. Research output has increased significantly, particularly after 2020, aligning with key clinical trials on SGLT2 inhibitors. The most prolific journals included Cardiovascular Diabetology, Journal of the American College of Cardiology, and European Journal of Heart Failure. Leading institutions such as Harvard Medical School, University of Toronto, and University of Groningen were identified as major contributors. Citation analysis highlighted high-impact studies on SGLT2 inhibitors’ cardiovascular and renal benefits. Keyword co-occurrence analysis showed that heart failure, diabetes mellitus, and renal protection were dominant themes. The United States, Germany, and China emerged as major players in global collaborations, shaping the research landscape.
Conclusion: The bibliometric findings suggest that research on SGLT2 inhibitors in cardiovascular diseases is rapidly evolving, with increasing global contributions and high-impact publications shaping clinical applications. Future studies should focus on long-term cardiovascular and renal outcomes, mechanistic insights, and comparative effectiveness research to further establish SGLT2 inhibitors’ role in cardiovascular medicine.
Anahtar Kelimeler
SGLT2 inhibitors cardiovascular diseases heart failure bibliometric analysis citation impact
Etik Beyan
This study is a bibliometric analysis conducted solely using publication data obtained from open-access databases; therefore, it does not require ethical committee approval
Kaynakça
- Chen B, Wang X, Pan D, Wang J. Global trends and hotspots in the association between chronic kidney disease and cardiovascular diseases: a bibliometric analysis from 2010 to 2023. Cardiorenal Med. 2025;15(1): 1-20. doi:10.1159/000542441
- Wang J, Su Y, Li Y, Su T, Li Y. A bibliometric analysis of research hotspots and frontiers in diabetes and cardiovascular disease comorbidity from 2005 to 2024. medRxiv. 2024;2024:9. doi.org/10.1101/ 2024.09.29.24314577
- Chen L, Ma S, Hu D, et al. Bibliometric study of sodium glucose cotransporter 2 inhibitors in cardiovascular research. Front Pharmacol. 2020;11:561494. doi:10.3389/fphar.2020.561494
- Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG outcome study. Diabetes Care. 2016;39(5):717-725. doi:10.2337/dc16-0041
- McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148-158. doi: 10.1001/jamacardio.2020.4511
- Zou CY, Liu XK, Sang YQ, Wang B, Liang J. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis. Medicine (Baltimore). 2019;98(49):e18245. doi:10.1097/MD. 0000000000018245
- Pan R, He Y, Melisandre W, et al. Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases. Front Pharmacol. 2024;15: 1437760. doi:10.3389/fphar.2024.1437760
- Cardoso R, Graffunder FP, Ternes CM, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis. EClinicalMedicine. 2021;36:100885. doi:10.1016/j.eclinm.2021.100933
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263-e421. doi:10.1016/j.jacc.2021.12.012
- Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587-597. doi:10.1161/CIRCULATIONAHA.113.005081
- Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752-772. doi:10.1161/CIRCULATIONAHA.116.021887
- McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148-158. doi: 10.1001/jamacardio.2020.4511
- Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632-644. doi:10.1016/j.jacbts. 2020.02.004
- Toyama T, Neuen BL, Jun M, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(5):1237-1250. doi:10.1111/dom.13648
- Barbarawi M, Al-Abdouh A, Barbarawi O, Lakshman H, Al Kasasbeh M, Chen K. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. Heart Fail Rev. 2021;26(2):1-10. doi:10.1007/s10741-021-10083-z
- Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diabetes Vasc Dis Res. 2012;9(2):117-123. doi: 10.1177/1479164112441190
- Lo KB, Gul F, Ram P, et al. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. Cardiorenal Med. 2020;10(1):1-10. doi:10.1159/ 000503919
Öz
Amaç: Sodyum-glukoz kotransportör 2 (SGLT2) inhibitörleri, yalnızca glukoz kontrolünün ötesinde sundukları kardiyoprotektif ve renoprotektif etkiler nedeniyle kardiyovasküler bilim alanında önemli bir ilgi görmüştür. Son on yılda bu alandaki araştırmalar hızlı bir şekilde artmıştır. Bu çalışma, 2014–2024 yılları arasında SGLT2 inhibitörlerinin kardiyovasküler hastalıklardaki rolüne ilişkin küresel araştırma eğilimlerini değerlendiren bir bibliyometrik analiz yapmayı; yayın çıktıları, atıf etkisi, etkili araştırmacılar, anahtar kelime eğilimleri ve uluslararası iş birliği ağlarını incelemeyi amaçlamaktadır.
Yöntemler: Bibliyometrik analiz, Web of Science (WoS) Core Collection veritabanı kullanılarak gerçekleştirilmiş olup, 1 Ocak 2014 ile 31 Aralık 2024 tarihleri arasında "Cardiac Cardiovascular System" kategorisinde yayımlanan makalelere odaklanılmıştır. Yazar iş birlikleri, kurumsal bağlantılar, anahtar kelime eşgörünümleri ve atıf dağılımları VOSviewer yazılımı ile görselleştirilmiştir.
Bulgular: Toplam 1.271 makale analiz edilmiştir. Araştırma çıktılarında özellikle 2020 sonrası belirgin bir artış gözlemlenmiş olup, bu durum SGLT2 inhibitörleriyle ilgili önemli klinik çalışmalarla örtüşmektedir. En üretken dergiler arasında Cardiovascular Diabetology, Journal of the American College of Cardiology ve European Journal of Heart Failure yer almıştır. Harvard Tıp Fakültesi, Toronto Üniversitesi ve Groningen Üniversitesi gibi önde gelen kurumlar başlıca katkı sağlayıcılar olarak öne çıkmıştır. Atıf analizi, SGLT2 inhibitörlerinin kardiyovasküler ve böbrek faydalarına odaklanan yüksek etkili çalışmaları ön plana çıkarmıştır. Anahtar kelime eşgörünüm analizinde kalp yetmezliği, diabetes mellitus ve böbrek koruması baskın temalar olarak öne çıkmıştır. Amerika Birleşik Devletleri, Almanya ve Çin, küresel iş birliği ağı içinde önemli aktörler olarak belirlenmiş ve araştırma alanının şekillenmesinde etkili olmuştur.
Sonuç: Bibliyometrik bulgular, SGLT2 inhibitörlerinin kardiyovasküler hastalıklardaki araştırma alanının hızla geliştiğini, küresel katkıların arttığını ve klinik uygulamaları şekillendiren yüksek etkili yayınların ortaya çıktığını göstermektedir. Gelecekteki çalışmalar, uzun vadeli kardiyovasküler ve renal sonuçlara, mekanistik açıklamalara ve karşılaştırmalı etkinlik araştırmalarına odaklanmalıdır; böylece SGLT2 inhibitörlerinin kardiyovasküler tıptaki yeri daha sağlam bir şekilde ortaya konulabilir.
Anahtar Kelimeler
SGLT2 inhibitörleri kardiyovasküler hastalıklar kalp yetmezliği bibliyometrik analiz atıf etkisi
Kaynakça
- Chen B, Wang X, Pan D, Wang J. Global trends and hotspots in the association between chronic kidney disease and cardiovascular diseases: a bibliometric analysis from 2010 to 2023. Cardiorenal Med. 2025;15(1): 1-20. doi:10.1159/000542441
- Wang J, Su Y, Li Y, Su T, Li Y. A bibliometric analysis of research hotspots and frontiers in diabetes and cardiovascular disease comorbidity from 2005 to 2024. medRxiv. 2024;2024:9. doi.org/10.1101/ 2024.09.29.24314577
- Chen L, Ma S, Hu D, et al. Bibliometric study of sodium glucose cotransporter 2 inhibitors in cardiovascular research. Front Pharmacol. 2020;11:561494. doi:10.3389/fphar.2020.561494
- Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG outcome study. Diabetes Care. 2016;39(5):717-725. doi:10.2337/dc16-0041
- McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148-158. doi: 10.1001/jamacardio.2020.4511
- Zou CY, Liu XK, Sang YQ, Wang B, Liang J. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis. Medicine (Baltimore). 2019;98(49):e18245. doi:10.1097/MD. 0000000000018245
- Pan R, He Y, Melisandre W, et al. Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases. Front Pharmacol. 2024;15: 1437760. doi:10.3389/fphar.2024.1437760
- Cardoso R, Graffunder FP, Ternes CM, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis. EClinicalMedicine. 2021;36:100885. doi:10.1016/j.eclinm.2021.100933
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263-e421. doi:10.1016/j.jacc.2021.12.012
- Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587-597. doi:10.1161/CIRCULATIONAHA.113.005081
- Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752-772. doi:10.1161/CIRCULATIONAHA.116.021887
- McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148-158. doi: 10.1001/jamacardio.2020.4511
- Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632-644. doi:10.1016/j.jacbts. 2020.02.004
- Toyama T, Neuen BL, Jun M, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(5):1237-1250. doi:10.1111/dom.13648
- Barbarawi M, Al-Abdouh A, Barbarawi O, Lakshman H, Al Kasasbeh M, Chen K. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. Heart Fail Rev. 2021;26(2):1-10. doi:10.1007/s10741-021-10083-z
- Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diabetes Vasc Dis Res. 2012;9(2):117-123. doi: 10.1177/1479164112441190
- Lo KB, Gul F, Ram P, et al. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. Cardiorenal Med. 2020;10(1):1-10. doi:10.1159/ 000503919
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Kardiyoloji |
| Bölüm | Orijinal Makale |
| Yazarlar | |
| Yayımlanma Tarihi | 30 Mayıs 2025 |
| Gönderilme Tarihi | 31 Mart 2025 |
| Kabul Tarihi | 5 Mayıs 2025 |
| Yayımlandığı Sayı | Yıl 2025 Cilt: 8 Sayı: 3 |
Üniversitelerarası Kurul (ÜAK) Eşdeğerliği: Ulakbim TR Dizin'de olan dergilerde yayımlanan makale [10 PUAN] ve 1a, b, c hariç uluslararası indekslerde (1d) olan dergilerde yayımlanan makale [5 PUAN]
Dahil olduğumuz İndeksler (Dizinler) ve Platformlar sayfanın en altındadır.
Not: Dergimiz WOS indeksli değildir ve bu nedenle Q olarak sınıflandırılmamıştır.
Yüksek Öğretim Kurumu (YÖK) kriterlerine göre yağmacı/şüpheli dergiler hakkındaki kararları ile yazar aydınlatma metni ve dergi ücretlendirme politikasını tarayıcınızdan indirebilirsiniz. https://dergipark.org.tr/tr/journal/2316/file/4905/show
Dergi Dizin ve Platformları
Dizinler; ULAKBİM TR Dizin, Index Copernicus, ICI World of Journals, DOAJ, Directory of Research Journals Indexing (DRJI), General Impact Factor, ASOS Index, WorldCat (OCLC), MIAR, EuroPub, OpenAIRE, Türkiye Citation Index, Türk Medline Index, InfoBase Index, Scilit, vs.
Platformlar; Google Scholar, CrossRef (DOI), ResearchBib, Open Access, COPE, ICMJE, NCBI, ORCID, Creative Commons vs.